Catabasis Pharmaceuticals Inc. says it will pursue higher dosing after its edasalonexent (CAT-1004) failed in the Phase II MoveDMD clinical trial testing the drug in Duchenne muscular dystrophy and the company will analyze different efficacy measures.
Catabasis reported Jan. 31 that the drug did not meet endpoints related to MRI T2 measures of leg muscles. Two...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?